ALBUQUERQUE, N.M, March 3, 2010 -- Biomoda, Inc. (OTCBB: BMOD and Advanced Medical Imaging and Genetics (Amigenics) (www.amigenics.com), an innovative medical clinic specializing in prevention and early detection of disease, announced their intent to collaborate on a variety of projects to advance technology for the early detection of lung and other cancer.
“Amigenics is at the forefront of individualized health care using state-of-the-art imaging and diagnosis,” said John Cousins, President of Biomoda. “We are excited about the prospect of collaborating with them and strengthening both companies.”
Amigenics’ staff of physicians and genetic counselors offer personalized disease risk screening, clinical evaluations, genetic counseling and treatment plans for a variety of conditions that affect adults. Amigenics’ Las Vegas, Nevada, clinic combines comprehensive medical evaluations with the revolutionary technologies of advanced medical imaging and genetics.
Cousins said the two companies will pursue initiatives that complement their businesses. Biomoda is seeking Food and Drug Administration (FDA) approval of its cytology-based screening technology as a Class III medical device. Multi-site Phase III trials, the final step before FDA approval, are scheduled to begin in 2010.
“I anticipate that our Phase III trials will incorporate a variety of advancements in the methods of collection, data correlation, and imaging due to our collaboration with Amigenics,” said Cousins. “We always are looking to partner with companies leading the pack, and Amigenics certainly is a leader.”
Biomoda is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer in large populations. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.
About Biomoda
Biomoda is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. Current research and development operations, laboratory functions and administrative offices are located in Albuquerque, NM.
Forward-Looking Statements
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are made as of the date of this document and are subject to change without notice.
Contact:
Biomoda, Inc.
John Cousins,
505-821-0875